argenx NV ADR (ARGX)vsCorcept Therapeutics Incorporated (CORT)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
CORT
Corcept Therapeutics Incorporated
$112.79
-1.85%
HEALTHCARE · Cap: $12.32B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 540% more annual revenue ($5.32B vs $830.81M). ARGX leads profitability with a 32.3% profit margin vs 6.6%. CORT appears more attractively valued with a PEG of 0.81. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CORT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Intrinsic value data unavailable for CORT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 31.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Earnings expanding 24.1% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Trading at 17.2x book value
ROE of 7.8% — below average capital efficiency
6.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : CORT
The strongest argument for CORT centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 31.7% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CORT
The primary concerns for CORT are Price/Book, Return on Equity, Profit Margin. A P/E of 253.3x leaves little room for execution misses.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CORT is a hypergrowth play — different risk/reward profiles.
CORT carries more volatility with a beta of 0.45 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 60/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Corcept Therapeutics Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?